Safety and Efficacy of Arterially Directed Liver Therapies in the Treatment of Hepatic Metastatic Ovarian Cancer: A Retrospective Single-Institution Study

被引：3

作者：

Lacayo, Eduardo A. ^{[1
]}

Velayati, Sara ^{[1
]}

Elsakka, Ahmed ^{[1
]}

Brody, Lynn ^{[1
]}

Erinjeri, Joseph P. ^{[1
]}

Ziv, Etay ^{[1
]}

Boas, Franz E. ^{[1
]}

Sofocleous, Constantinos T. ^{[1
]}

Silk, Mikhail ^{[3
]}

Makker, Vicky ^{[2
]}

Tew, William P. ^{[2
]}

Yarmohammadi, Hooman ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, Intervent Radiol Serv, 1275 York Ave,Suite H-118, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Gynecol Med Oncol Serv, New York, NY 10065 USA

[3] Univ Penn, Div Intervent Radiol, Dept Radiol, Philadelphia, PA 19104 USA

来源：

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY | 2021年 / 32卷 / 06期

关键词：

RADIOEMBOLIZATION; MICROSPHERES; BREAST;

D O I：

10.1016/j.jvir.2020.11.011

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Purpose: To evaluate the safety and efficacy of 2 locoregional therapies (LRTs) including hepatic artery embolization (HAE) and transarterial radioembolization (TARE) in the treatment of patients with metastatic ovarian cancer to the liver. Material and Methods: From October 2010 to May 2019, the data of 15 consecutive patients (median age, 54 years +/- 9.8; range, 35- 78 years) with hepatic metastatic ovarian cancer who were treated with either HAE (n = 6; 40%) or TARE (n = 9; 60%) were reviewed. The most common histopathologic type was epithelial ovarian carcinoma (80%). The most common chemotherapy regimens used prior to embolization included carboplatin, paclitaxel, cisplatin, and bevacizumab. Patients received a mean of 4 lines +/- 3 (range, 1-9) of chemotherapy. All patients with serous carcinoma were resistant to platinum at the time of embolization. Indications for embolization were progression of disease to the liver while receiving chemotherapy in 14 (93.3%) patients and palliative pain control in 1 patient. Results: The overall response rates at 1, 3, and 6 months were 92.4%, 85.6%, and 70%, respectively. Median overall survival from the time of LRT was 9 (95% confidence interval [CI], 4-14) months. Median local tumor progression was 6.4 months +/- 5.03 (95% CI, 3.3- 9.5). No grade 3-5 adverse events were detected in either group. Conclusions: HAE and TARE were well tolerated in patients with metastatic ovarian cancer to the liver and possibly ensured prolonged disease control in heavily treated, predominantly in patients resistant to platinum. Larger numbers are needed to verify these data.

引用

页码：853 / 860

页数：8